Related Experiment Videos
Systemic lupus erythematosus and B-cell hematologic neoplasm
1Comprehensive Cancer Center and Department of Medicine, Our Lady of Mercy Medical Center, New York Medical College, Bronx 10466, USA.
Lupus
|January 15, 2002
Summary
Systemic lupus erythematosus (SLE) and B-cell malignancies often co-occur. Research suggests independent clinical courses and explores potential links like PTEN gene defects, B-cell accumulation, and EBV infection.
Area of Science:
- Immunology and Oncology
- Rheumatology
Background:
- The association between systemic lupus erythematosus (SLE) and B-cell malignancies is frequently observed.
- This study investigates nine cases of concurrent SLE or discoid lupus erythematosus (DLE) with lymphoma or plasma cell disorders.
Observation:
- B-cell malignancies can precede, follow, or occur simultaneously with SLE diagnosis and treatment.
- The age of onset for B-cell neoplasms in SLE patients is comparable to the general population.
- Concurrent SLE and B-cell malignancy cases often exhibit independent clinical trajectories.
Findings:
- Common B-cell malignancies include lymphoma and plasma cell disorders.
- Mortality is linked to progressive neoplasm, sepsis, or both.
- The role of immunosuppressive drugs in SLE patients prior to lymphoma is a consideration.
Implications:
- Potential mechanisms linking SLE and B-cell malignancy include PTEN gene defects affecting apoptosis, accumulation of self-reactive B-cells, and Epstein-Barr virus (EBV) infection.
- Further research into these pathways is warranted to understand the pathogenesis of these co-occurring conditions.
- Understanding these links may inform future therapeutic strategies for patients with both SLE and B-cell malignancies.